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Background: Cancer of the breast is a major health burden and the most common cancer among women
worldwide. Though its incidence is fourfold greater in high-income countries, in sharp contrast, mortality rates are
greatest among the low-income countries. Early detection linked to appropriate treatment is the most effective
strategy to improve survival. The purpose of this study therefore was to establish the survival experiences of women
with breast cancer at a Ugandan hospital.
Methods: This study is an observational analytical study. It involved 262 women during the periods 2004 to 2007
and 2010 to 2012. Kaplan Meier method and Cox regression were used to calculate breast cancer mortality and
cumulative survival experiences.
Results: Sixty-three out of 262 (23 %) deaths were observed; mean age was 45 years, and 91 observations ended
on or before follow-up. Luminal B median survival was months. The 5-year cumulative survival was 51.8 %. There
were no stage I and II deaths. There were no differences in survival by phenotype adjusted for age, but there were
differences for stage IV (p = 0.05).
Conclusions: The cumulative 5-year survival was 51.8 %. The burden of advanced disease and associated mortality
were high, and a significant number of patients were lost to follow-up after their first contact.
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Breast cancer remains the most common cancer in
women globally and only second to cervical cancer
among Ugandan women (excluding HIV-related Kaposi’s
sarcoma) [1]. It is estimated that worldwide, over half a
million women died in 2011 due to breast cancer [2].
Although breast cancer was previously thought to be a
disease of the developed world, almost 50 % of breast
cancer cases and 58 % of deaths occur in less developed
countries [1].
Breast cancer among Ugandan women as is seen
among other black women in North America and
Europe is characterized by poor survival experiences,
aggressive behavior, and late stage at presentation, and a
significant population is found among young women less
than 40 years of age [3–6].* Correspondence: mosesg@img.co.ug
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creativecommons.org/publicdomain/zero/1.0/The reasons for these disparities in epidemiology and
tumor behavior are a subject of much speculation and
interest [3, 7, 8]. Breast cancer survival experiences vary
greatly worldwide, ranging from 80 % or over (cumula-
tive 5-year survival) in North America, Sweden, and
Japan to around 60 % in middle-income countries and
below 40 % in low-income countries [9]. Early detection
linked to appropriate treatment is currently the most
effective strategy to reduce breast cancer mortality. The
low survival in less developed countries can be explained
mainly by the lack of early detection programs and
awareness resulting in a high percentage of women
presenting with late stage disease, as well as lack of
adequate treatment facilities [10, 11]. Whereas we now
know that breast cancer has different subtypes (catego-
rized by hormonal receptor status) and furthermore
know that the prognosis for the different subtypes is
different, we have not at all or conclusively examined
survival by molecular subtypes in Uganda and the East
African region. In addition, there is paucity of publishedss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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general and the East African region in particular.
In this study, we examined breast cancer survival ex-




This study is an observational analytical study.
Study site
Mulago Hospital where this study was conducted is one
of the two national referral hospitals in Uganda with a
1500-bed capacity and with over 400 physicians. The
Ugandan Cancer Institute (UCI) housed on the same
campus as Mulago Hospital is the only specialized public
cancer treatment center in the country.
Sample collection
Patients with histological diagnosed breast cancer dur-
ing the period 2004–2007 and 2010–2012 were sam-
pled for inclusion in the study. The case definition
was a histologically confirmed invasive breast cancer
in female patients.
Formalin-fixed and paraffin-embedded blocks for the
2004–2007 participants were retrieved from the archives
in the Department of Pathology College of Health Sci-
ences, Makerere. The department serves both Mulago
Hospital and the UCI and matched them with corre-
sponding demographic and clinical data from UCI re-
cords department.
Patients with non-available clinical data were excluded.
The 2010–2012 participants were recruited prospect-
ively, and the tissue samples were analyzed as soon as
they were obtained.
Inclusion and exclusion criteria
Patients with single primary, incident, invasive breast
cancer diagnosed within the specified consecutive calen-
dar period with a potential follow-up period of 2–5 years
were included. Duplicate cases were excluded.
The period between 2008 and 2009 had significant
missing files and specimen so it was excluded from what
would have been a 2004–12 study period.
Follow-up
A follow-up period of 2 years for the 2010–12 group
and of 5 years for 2004–7 was imposed. Complete
follow-up was achieved when vital status (alive/dead) at
the applicable closing date was known for an individual.
If not known, then the follow-up was incomplete.
We employed predominantly active follow-up methods.
Information on deaths was sourced from patient clinical
data files for scheduled and unscheduled return visits. Thisincluded repeated periodic scrutiny of medical records at
UCI and the breast unit in Mulago, visits to Hospice
Uganda, and enquiries with attending physicians. In
addition, telephone enquiries from patients or persons
known to them were made, and we also checked at the
Makerere University cancer registry database.
Censoring
With a closing date of follow-up for the subjects that
dropped out or lost before the closing period were con-
sidered censored. When the loss was due to a factor un-
related to the study outcome, it was termed random
(non-informative censoring). When it occurred due to a
factor related to the study outcome death, then it was
considered non-random or informative censoring.
The Cox model was used, and the determinants tested
for association with loss to follow-up were age at diag-
nosis and stage of disease.
Index date and closing date to follow-up
The index date is the starting date for calculation of
survival, and this was the first date of unequivocal
diagnosis of cancer by means of histological diagnosis.
The inclusion dates were between the 1st of January
2004 to the 31st of December 2007 and the 1st of
January 2011 to the 31st of December 2012 with a
closing date on the 1st of January 2009 to the 31st of
December 2014, respectively.
Survival time
Survival time was calculated at the time (in months or
completed years) between the index date and the date of
death, date of loss to follow-up, or the closing date,
whichever was earliest.
Other variables
Age at diagnosis was defined as the age in completed
years on the incidence date, and age was not necessarily
verified with birth certificates.
Clinical extent of disease: Manchester staging was
used, stages I, II, III, and IV:
Stage I. Growing but localized disease only
Stage II.Growing localized disease ± nodal involvement
Stage III.Growing locally advanced disease (involving
chest wall, skin) ± nodal involvement
Stage IV.Metastatic disease
In the 2004–7 period, 383 files were retrieved; 213
were excluded either because pathology blocks could not
be identified or clinical notes were grossly insufficient,
leaving 170 files. Fifty-four of these were excluded either
because the histopathological analyses were inconclusive
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that were included in the study.
In the 2010–12 period, 180 participants data were
considered, 34 were non-malignant and were excluded,
and 146 were included in the study (see Fig. 1).
Data quality indices
All cases had histologically confirmed breast cancer
diagnosis. The cases registered based on death certifica-
tion only were nil.
Statistical analysis: estimation of survival probability
We used life tables Kaplan Meier and Cox regression as
the tool to describe the mortality experience of this
hospital-based case series.
We chose these methods of estimating survival prob-
ability because they handle censoring by assuming it to
be random. They permitted the calculation of the cumu-
lative of survival at time from the conditional probabil-
ities of survival during intervals of follow-up time. The
number of cases censored during the interval, because of
loss to follow-up or withdrawal, was shown.
Subjects who experienced the outcome during each
interval were indicated. The effective number of subjects
at risk during each interval was calculated.
The starting point was defined as the date of the first
diagnosis; the outcome of interest was death. The end
point was a binary variable (alive or dead). The calcula-
tion of survival time involved patient accrual period dur-
ing which patients were recruited and followed up, and
closing date for analysis was defined as 2–5 years.
The probability (risk) of dying was calculated by year
5. Cumulative survival probabilities were calculated sep-
arately for stage, age, and phenotype. Statistical tests for
formal comparison of the different survival curves wereFig. 1 Patient recruitment chart from the 2004–2007 and 2010–12 cohortsdone by log rank test to assess for statistical significance
of differences observed.
All data were analyzed using STATA version 12.Ethical consideration
The study was approved by the Makerere University
College of Health Sciences School of Medicine Research
and Ethics Committee and was registered with Uganda
National Council of Science and Technology.Evaluation of ER, PR, and HER2 status and quality
assurance
We used the quality assurance guidelines of the College
of American Pathologists (CAP). The laboratory had
control tissue, which has proven positive for each of the
antibodies; a section of the positive control was used at
every run of the day, and a negative control was run.
Paraffin specimens were cut into four sections and
mounted on positively charged slides. The slides were
paraffinized and rehydrated in xylene followed by graded
alcohols, then washed in Tris-buffered saline. The
immunohistolochemical assays were performed using an
immunostainer with antibodies and antigen unmasking.
Appropriate negative controls for the immunostaining
were prepared by omitting the primary antibody step.
The results were scored semi quantitatively using Rein-
er’s four-point scale based on intensity and percentage
of IHC reaction; HER2 staining were evaluated accord-
ing to manufacturer’s instructions [12].
Antibodies used were the following: ER (clone SP-I),
ASR PR (clone Y85), ASR and HER2/neu (c-erbB-2), and
clone CB-11). The manufacturer for all was Cell
marquee corporation, Rocklin, CA 95677.
Table 1 Characteristics of breast cancer survival study
participants, Uganda 2014
Variable Number












Unspecified or missing 19
Cumulative survival 0.518
Observed events (death)
Mean age 45.3 years
Deaths
≥40 years 32 (50.1 %)
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Hematoxylin and eosin (H&E) staining was performed
first to confirm diagnosis of invasive breast cancer be-
fore immunostaining. The histological type and grade
were determined. A consultant pathologist(s) and labora-
tory technicians received all the histological slides, and
the tumors were classified according to Nottingham
modification of the Scorff Bloom Richardson criteria
[13]. Based on histology, tumors were classified into the
following groups: invasive ductal carcinoma (NoS), lobu-
lar, medullary, papillary, and colloid.
Results
Data from a cohort of 262 women diagnosed with
breast cancer at Mulago Hospital and UCI during the
years 2004–7 and 2010–12 and followed up from the
point of diagnosis were included in assessment of
their survival experience.
Sixty-three events were recorded, 56 with specified
sub types, and 7 with undetermined subtypes; 91 partici-
pants made only one contact visit to the health facility.
The mean age of the study participants was 45 years
6 months. The majority were stage III and IV 187/262
(71 %). Subtypes triple-negative breast cancer (TNBC)
and HER2+ contributed 124/243 (51 %) of verified sub-
types. The mean age of observed events (deaths) was
45.3 years. There were no deaths recorded for stage I
and II disease (see Table 1).
The luminal B group had median survival time of
28 months, and the rest did not reach the 50 % with
probability of failure (death) on the KM curve. However,
25 % of subjects in TNBC group failed by 16 months, in
luminal A were 18 months, luminal B 14 months, and
HER2+ by 36 months (see Table 2).
The probability of death by stage
The differences in probability of dying by stage (hazard)
were significant p < 0.001 (Cox Breslow method for ties).
The odds of dying were higher for stage IV disease
followed by stage III (see Fig. 2).
In Fig. 2, the “unknown” curve represents missing or
inconclusive staging.
In Fig. 3, survival by phenotype is demonstrated
p = 0.2941. Her2+ and TNBC show better survival
probabilities, however, when adjusted for age and
stage (see Fig. 4). HER2+ and TNBC showed the low-
est survival probabilities.
The stage III and IV survival probabilities were less
than 0.4 at 5 years (60 months) (see Table 3).
Discussion
Clinical advances in breast cancer treatment during the
past five decades have led to major improvement in
health outcomes including longer disease free survival,
Table 1 Characteristics of breast cancer survival study









Unspecified or missing 3
Galukande et al. World Journal of Surgical Oncology  (2015) 13:220 Page 5 of 8less surgical mutilation, and increasing individualization
of treatment [14–16]. In addition to improved early de-
tection, successful treatment of regional disease with
nodal involvement has also made some dent on late
stage mortality [14]. These facts hold true mostly for
high-income countries. In upper and middle-income
countries, five-year survival rates are consistently over
80 %, in sharp contrast, survival falls as low as 12 % inTable 2 Cumulative survival probabilities by subtypes, a breast
cancer study, 2014
Time Survivor function Std. error [95 % Conf. int.]
TNBC 0 1 – –
12 0.837 0.053 0.6994 0.9153
24 0.6647 0.0719 0.5034 0.7843
36 0.6647 0.0719 0.5034 0.7843
48 0.6136 0.0826 0.4325 0.7523
60 0.4832 0.1048 0.2711 0.6668
Luminal A 0 1 – –
12 0.8355 0.0477 0.7155 0.9081
24 0.6593 0.0622 0.5223 0.7655
36 0.5539 0.0719 0.4031 0.6810
48 0.5113 0.078 0.3509 0.6507
60 0.4601 0.0853 0.2895 0.6150
Luminal B 0 1 – –
12 0.8125 0.0976 0.5246 0.9354
24 0.5909 0.1302 0.3026 0.7933
36 0.3152 0.1623 0.0628 0.6177
48 0.3152 0.1623 0.0628 0.6177
60 0.3152 0.1623 0.0628 0.6177
Her2+ 0 1 – –
12 0.92 0.0543 0.7164 0.9794
24 0.805 0.0897 0.5524 0.9238
36 0.7245 0.1111 0.4409 0.8809
48 0.7245 0.1111 0.4409 0.8809
60 0.4528 0.1695 0.1353 0.7307low-income countries such as in Gambia [17]. A recent
population-based study put the 5-year survival in
Uganda at 44 % [18].
The possible reasons for the poorer survival rates in
low-income countries are varied and include but not
limited to the following: delayed individual health seek-
ing behavior, low socio economic circumstances, limita-
tions and inadequacies in health systems, and a lack of
prioritization for non communicable diseases [10, 11, 19,
20]. And more specifically, lack of capacity to do early
detection as well as adequate diagnostic and treatment
facilities [21, 22].
In a recent Ugandan study [19], women delayed up to
120 months before seeking appropriate breast cancer
care with such excessive delays play a part in allowing
tumors to advance in stage. In the same study, 89 %
were stage III and IV (late) stage disease [19].
Participants with stage I and II had survival probabil-
ities of 1 (100 %), and no death was recorded in this cat-
egory over the 5-year period. This matches or nearly
matches the experiences recorded in the high-resourced
settings where a 10-year survival probability is equal or
more than 97 % for stage I and II disease [9].
The survival for early disease was high despite all the
health service delivery limitations. This implies that we
do have an opportunity to improve survival only if we
make early diagnoses. We therefore recommend urgent
and considerable investment in understanding the
drivers of late disease presentation and encourage
women to report symptoms at the earliest opportunity
but also for the women to demand for appropriate
screening regularly.
The cumulative survival after 5 years in this study
was 51.8 %, a little higher than what is shown for
low-income countries. Although with these data, the
overall median survival rate was not reached; only
the median survival for luminal B sub type was de-
termined which was 28 months. To reach the me-
dian survival rate, more time would be needed to
accumulate 50 % events (probability in this case was
death). This was a hospital-based case series strictly
speaking not comparable to population-based stud-
ies. This rate 51.8 % could have been an overesti-
mate given the number of patients censored.
Half of the women who died were 40 years old or
younger with a mean age of 45 years. This adds to
the characterization of breast cancer disease land-
scape in Uganda a low-income country in sub-
Saharan Africa. The majority (89 %) was stage III
and IV. Stage IV disease is metastatic and patients
normally die from complications of metastases. In
this study, the majority (of those) who died were
stage III. This stage was not revised at the time of
death so it is likely that most if not all had advanced
Fig. 2 Probability of death by stage
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text mostly involved a plain chest X-ray, abdomino-pelvic
ultra sound scanning. In some few cases CT-scan, MRI
scan, or bone scans were used. The latter poses better pre-
cision but are mostly inaccessible in the low resourced en-
vironments, like this one. With inadequate high-precision
staging capacity, the tumor spread (stage) at diagnosis was
likely to be under assessed.
This study revealed that more than a third of women
(35 %) with breast cancer were lost to follow-up under
one year, after only one contact with the facility. This
could be due to several factors (though this study did
not investigate them). Some could have died, others
could have sought other opinions elsewhere especially
from alternate medicine sources (herbal, spiritual or
traditional healers). It is also possible that they found
considerable challenges in navigating a complex healthFig. 3 Survival by phenotypecare system, which does not have dedicated patient navi-
gators to help patients work their way through it. The
majority of these patients have low level formal educa-
tion and may be unfamiliar with dealings in an urban
hospital setting. Irrespective of the reasons, this was a
significant loss to follow-up that warrants specific atten-
tion to mitigate further losses in the future. These losses
imply impeded access (barriers) to appropriate and or
prompt cancer care. These impediments need to be
tackled urgently. Forty percent had TNBC and HER2+
cancer phenotypes; these phenotypes carried the
lowest survival rates in this study. These were ER-
negative tumors and not amenable to anti-hormonal
therapy. For TNBC and HER2+, targeted therapies are
recommended but normally not affordable to most
patients, since the public service often does not stock
them.
Fig. 4 Survival by stage-adjusted for age and phenotype
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that involve follow-up of patients for long periods of
time especially in our context. They include but not
limited to a lack of identifiable physical address, reli-
able phone contacts, high rate of migration from
place to place, traveling long distances, mistrust in
health care system, availability and use of unlicensed
practitioners (traditional healers) who normally keep
no records and do not communicate with the main
stream health care system [22, 23]. Secure record
storage and accurate recording are also considerable
challenges for field studies. These barriers put to-
gether make it impossible for the majority of our
patients to have the best possible chance to survive
their own experience of this disease.
Study limitations and strengths
Although the date of onset of the disease would seem
more appropriate for defining the start of counting sur-
vival time, the date for first diagnosis is used in such
studies. It is generally observed that the time lag be-
tween onset of symptoms and presenting to hospital forTable 3 Summarizes the survival function of the different stages, a b
Time (months) I and II III
Survival probability Survival probability
95 % CI 95 % CI
0 1 1
12 1 0.8446 0.7553 0.9
24 1 0.6204 0.5124 0.7
36 1 0.5236 0.4073 0.6
48 1 0.4909 0.3653 0.6
60 1 0.3442 0.2029 0.4a diagnosis to be made may be long, therefore leading to
an under estimate in survival measuring.
A possibility of under reporting deaths from other
causes may overestimate the cause specific survival
probabilities. It was difficult to establish whether the
cause of death was unrelated to breast cancer, as a
significant proportion of patients died at home, and
in addition, post mortems were not commonly done.
On the other hand, this study could have overesti-
mated cumulative survival due to a large number of
censored patients. Although an additional sense of
poor survival was given by the low number of pa-
tients at the end of the follow-up period.
Although cancer survival estimated from hospitals
case series at best reflects experiences of the selective
groups of patients in specific settings they cannot be
generalized as reflecting the overall efficiency of the can-
cer health services in a given country or region. In this
study, our findings reflect the enormous challenges faced
in initiating and completing treatment.
A sub analysis of survival by treatment type and com-
pletion was not done.reast cancer study, 2014
IV Missing/inconclusive
Survival probability Survival probability
95 % CI 95 % CI
1 1
033 0.689 0.4859 0.8251 0.9524 0.7072 0.9932
111 0.5414 0.3269 0.714 0.8844 0.6029 0.9706
274 0.4737 0.2546 0.6649 0.8844 0.6029 0.9706
048 0.4737 0.2546 0.6649 0.7861 0.4492 0.9302
902 0.3789 0.1562 0.6022 0.6289 0.2372 0.8611
Galukande et al. World Journal of Surgical Oncology  (2015) 13:220 Page 8 of 8Conclusions
Breast cancer survival was low, most patients had late
stage disease at presentation, a significant number did
not complete care (treatment), and many dropped out
before the first year was completed. TNBC and HER2+
carried the lowest survival rates. These data emphasize
the need for urgent and adequate investment in patient
support to complete treatment and follow-up. Further
exploration of the relationship between survival and
breast cancer molecular subtypes in the sub Saharan set-
ting is recommended.
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